A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias — Stella

Recruiting

Back to High-risk Myelodysplastic Syndrome trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(11 sites)

United States

City of Hope, Duarte, California

Stanford Medical Center, Palo Alto, California

Moffitt Cancer Center, Tampa, Florida

Northwestern Medicine, Chicago, Illinois

Dana Farber Cancer Institute, Boston, Massachusetts

Key details

Phase

Early testing

Sponsor

Crossbow Therapeutics, Inc.

Enrollment target

~72 participants

Started

July 2025

Primary completion

January 2027

Age range

12 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov